Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.

NCT02626572 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT02626572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02626572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
September 30, 2017
Enrollment
500 (estimated)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease